EP2451471A1 - Préparations d'insuline à effet retard - Google Patents

Préparations d'insuline à effet retard

Info

Publication number
EP2451471A1
EP2451471A1 EP10726993A EP10726993A EP2451471A1 EP 2451471 A1 EP2451471 A1 EP 2451471A1 EP 10726993 A EP10726993 A EP 10726993A EP 10726993 A EP10726993 A EP 10726993A EP 2451471 A1 EP2451471 A1 EP 2451471A1
Authority
EP
European Patent Office
Prior art keywords
arg
pro
asp
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10726993A
Other languages
German (de)
English (en)
Inventor
Isabell Schoettle
Christiane Fuerst
Verena Siefke-Henzler
Gerrit Hauck
Walter Kamm
Julia Schnieders
Jutta Carls
Gert Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of EP2451471A1 publication Critical patent/EP2451471A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to an aqueous pharmaceutical formulation with a
  • Type II diabetes is not generally deficient in insulin, but in a large number of cases, especially in advanced stages, treatment with insulin may be indicated
  • the replacement of the body's insulin secretion by exogenous, usually subcutaneous administration of insulin generally does not approach the above-described quality of the physiological regulation of blood glucose.
  • derailments of blood glucose go up or down, which in their most severe forms can be life-threatening could be.
  • increased blood glucose levels without initial symptoms represent a considerable health risk over years.
  • the large-scale DCCT study in the USA The Diabetes Control and Compounds Trial Research Group (1993) N. Engl. J. Med. 329, 977-986) showed clearly that chronically elevated blood glucose levels are significantly responsible for the development of late diabetic damage. Diabetic late damage is microvascular and macrovascular
  • Insulin preparations are achieved. Fast-acting formulations are given at meal times to compensate for the postprandial increase in blood glucose. Slow-acting basal insulins should ensure the basic supply of insulin, especially at night, without leading to hypoglycaemia.
  • Insulin is a 51 amino acid polypeptide distributed among 2 amino acid chains: the 21 amino acid A chain and the 30 amino acid B chain. The chains are linked by 2 disulfide bridges. Insulin preparations have been used for diabetes therapy for many years. Not only naturally occurring insulins are used, but more recently also insulin derivatives and analogues.
  • Insulin analogs are analogues of naturally occurring insulins, viz
  • Human insulin or animal insulins which differ in substitution of at least one naturally occurring amino acid residue with other amino acids and / or addition / removal of at least one amino acid residue from the corresponding otherwise identical naturally occurring insulin. These may also be amino acids that are not naturally occurring.
  • Insulin derivatives are derivatives of naturally occurring insulin or a
  • Insulin analog obtained by chemical modification.
  • the chemical modification may e.g. in the addition of one or more particular chemical groups to one or more amino acids.
  • insulin derivatives and insulin analogues have a slightly altered effect on human insulin.
  • EP 0 375 437 and EP 0 678 522 EP 0 124 826 relates inter alia. on substitutions of B27 and B28.
  • EP 0 678 522 describes insulin analogues which have different amino acids in position B29, preferably proline, but not glutamic acid.
  • EP 0 375 437 comprises insulin analogues with lysine or arginine in B28, which may optionally be additionally modified in B3 and / or A21.
  • Protected modifications are modified in the asparagine in B3 and at least one other amino acid in positions A5, A15, A18 or A21.
  • insulin derivatives and insulin analogues have a slightly altered effect on human insulin.
  • insulin analogs are described in which at least one amino acid of positions B1-B6 is replaced by lysine or arginine. Such insulins have a prolonged action according to WO 92/00321.
  • the insulin analogues described in EP-A 0 368 187 also have a delayed action.
  • the concept of intensified insulin therapy seeks to reduce the health risk by aiming for a stable control of blood sugar levels by early administration of basal insulin.
  • the insulin preparations on the market of naturally occurring insulin for insulin substitution differ in the source of insulin (e.g., beef, pork, human insulin) and the composition with which the profile of action (onset and duration of action) can be affected.
  • Insulins include insulin glargine (Gly (A21) Arg (B31) Arg (B32) human insulin) with a prolonged duration of action. Insulin glargine is injected as an acidic, clear solution and due to its solubility properties it falls in the physiological pH range of the
  • Insulin glargine is injected once daily and is distinguished from other long-acting insulins by its low serum profile and the associated reduction in the risk of nocturnal hypoglycemia (Schubert-Zsilavecz et al., 2: 125-130 (2001)).
  • the specific preparation of insulin glargine, which leads to the prolonged duration of action, is in
  • the B chain end consists of an amidated basic amino acid residue such as lysine or argininamide, i. in the amidated basic amino acid residue at the B chain end, the carboxyl group of the terminal amino acid is in its amidated form, and
  • the N-terminal amino acid residue of the insulin A chain is a lysine or arginine residue
  • the amino acid position A21 is occupied by a glycine residue
  • An object of the invention is therefore an aqueous pharmaceutical
  • a further subject of the invention is a pharmaceutical formulation as described above, in which the insulin analogue is selected from a group comprising:
  • Another object of the invention is a pharmaceutical formulation as described above, wherein the isotonizing agent is selected from a group containing mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, glycerol.
  • Another object of the invention is a pharmaceutical formulation as described above, having a pH in the range of pH 2.5 to 4.5, preferably in the range of pH 3.0 to 4.0, particularly preferably in the range of pH. 3 , 75th
  • Another object of the invention is a pharmaceutical formulation as described above, wherein the insulin, the insulin analogue and / or the insulin derivative is present in a concentration of 60-6000 nmol / ml
  • a further subject of the invention is a pharmaceutical formulation as described above in which glycerol is present in a concentration of 20 to 30 mg / ml, preferably in a concentration of 25 mg / ml.
  • a further subject of the invention is a pharmaceutical formulation as described above in which m-cresol is present in a concentration of 1 to 3 mg / ml, preferably in a concentration of 2 mg / ml.
  • Another object of the invention is a pharmaceutical formulation as described above in which zinc is present in a concentration of 0.01 or 0.03 or 0.08 mg / ml.
  • a further subject of the invention is a pharmaceutical formulation as described above, which additionally contains a glucagon-like peptide-1 (GLP1) or an analogue or derivative thereof, or exendin-3 or -4 or an analogue or derivative thereof ,
  • GLP1 glucagon-like peptide-1
  • Another object of the invention is a pharmaceutical formulation as described above, which additionally contains exendin-4.
  • Another object of the invention is a pharmaceutical formulation as described above in which an analog of exendin-4 is selected from a group containing
  • Another object of the invention is a pharmaceutical formulation as described above in which an analog of exendin-4 is selected from a group containing
  • Another object of the invention is a pharmaceutical formulation as described above, in which the peptide -LySo-NH 2 is added to the C-termini of the analogues of exendin-4.
  • Another object of the invention is a pharmaceutical formulation as described above in which an analog of exendin-4 is selected from a group containing
  • Another object of the invention is a pharmaceutical formulation as described above, in which in addition Arg 34 , Lys 26 (N ⁇ ( ⁇ -glutamyl (N ⁇ -hexadecanoyl))) GLP-1 (7-37) [liraglutide] or a pharmacologically tolerable salt thereof is included.
  • Another object of the invention is a pharmaceutical formulation as described above, in which the amino acid methionine is present, preferably in the concentration range of up to 10 mg / ml, more preferably of up to 3 mg / ml.
  • Another object of the invention is a method for producing a
  • Another object of the invention is a use of a formulation as described above for the treatment of diabetes mellitus.
  • Another object of the invention is a medicament for the treatment of
  • Diabetes mellitus consisting of a formulation as described above.
  • the preparation may further contain preservatives (e.g., phenol, cresol,
  • isotonizing agents e.g., mannitol, sorbitoi, lactose, dextrose,
  • Trehalose, sodium chloride, glycerol Buffer substances, salts, acids and alkalis and other excipients. These substances may be present individually or as mixtures.
  • Giycerol, dextrose, lactose, sorbitoi and mannitol are usually present in the pharmaceutical preparation in a concentration of 100-250 mM, NaCl in a concentration up to 150 mM.
  • Buffer substances e.g. Phosphate, acetate, citrate, arginine, glycylglycine or TRIS (i.e., 2-amino-2-hydroxymethyl-1, 3, -
  • Propandiol buffers and corresponding salts may be present in a concentration of 5-250 mM, preferably 10-100 mM.
  • Other excipients may include salts or arginine.
  • a further subject of the invention is a pharmaceutical formulation as described above in which the insulin analogue is in a concentration of 60-6000 nmol / ml (this corresponds approximately to a concentration of 0.35-70 mg / ml or 10-1000 Units / ml), preferably in a concentration of 240-3000 nmol / ml (this corresponds approximately to a concentration of 1.4-35 mg / ml or 40-500
  • the surfactant is present in a concentration of 5-200 ⁇ g / ml, preferably of 5-120 ⁇ g / ml and more preferably of 20-75 ⁇ g / ml.
  • Another object of the invention is a pharmaceutical formulation as stated above, in which glycerol and / or mannitol in a concentration of 100-250 mM, and / or NaCl preferably in a concentration up to 150 mM.
  • Another object of the invention is a pharmaceutical formulation as stated above, in which a buffer substance in a concentration of 5 - 250 mM is present.
  • Another object of the invention is a pharmaceutical insulin formulation, the further additives such. Contains salts which retard the release of insulin. Also mixtures of such sustained-release insulins described above
  • Formulations are included. Another object of the invention is a method for producing such pharmaceutical formulations. Likewise, another object of the invention is the use of such formulations for the treatment of diabetes mellitus.
  • Another object of the invention is the use or the addition of surfactants as a stabilizer during the production process of insulin,
  • Insulin analogues or insulin derivatives or their preparations are insulin analogues or insulin derivatives or their preparations.
  • Fig. 1 Hypoglycemic effect of new insulin analogues according to formula I in
  • Fig. 2 blood sugar lowering effect of new insulin analogues according to formula I in
  • Fig. 3 Hypoglycemic effect of YKL205 in the dog
  • Fig. 4 Zinc dependence of the hypoglycemic effect of YKL205 in the dog
  • the solution is prepared by adding about 25% water for injection.
  • One after the other are SAR161271 and the zinc chloride
  • the tonicity agent Glyceroi in the concentration 2.5% was selected.
  • the formulation is more stable compared to 0.8% NaCl as a tonicity agent.
  • precipitation was detected using NaCl during the preparation which was insoluble.
  • the osmolarity was 290 ⁇ 30 m ⁇ smol / kg for both substances.
  • m-cresol was chosen as a preservative. The concentration of 2 mg / ml was chosen, although 1.5 mg / ml would have been sufficient for preservation. Nevertheless, the higher m-cresol concentration was chosen due to microbiological safety aspects and specification specification. In addition, the formulations (except 2.1 mg / ml m-cresol) were placed on stability (3 months).
  • Example 4 Formulation of the amidated insulin derivatives
  • Examples 4 to 8 serve only to determine the biological, pharmacological and physicochemical properties of insulin analogues according to formula I by firstly providing formulations thereof (example 4) and then carrying out corresponding tests (examples 5 to 8).
  • a solution was prepared of the compounds as follows: The insulin analog according to the invention was dissolved at a target concentration of 240 ⁇ 5 ⁇ M in 1 mM hydrochloric acid with 80 ⁇ g / ml zinc (as zinc chloride).
  • compositions were used as solvent medium:
  • freeze-dried material was first about a 30% higher amount than due to the molecular weight and the desired
  • Target concentration of 240 ⁇ 5 ⁇ M the final solution was syringed with a 0.2 ⁇ m filter attachment into a with a septum and a crimp cap
  • Example 5 Evaluation of the hypoglycemic effect of new insulin analogues in the rat
  • the hypoglycemic effect of selected new insulin analogues is tested in male, healthy, normoglycemic Wistar rats.
  • Male rats are injected subcutaneously with a dose of 9 nmol / kg of an insulin analogue.
  • blood samples are taken from the animals and the blood sugar content is determined therein. The experiment clearly shows (see Fig. 1) that the insulin analog used according to the invention significantly delayed
  • Example 6 Evaluation of the hypoglycaemic effect of new insulin analogues in the dog
  • the hypoglycemic effect of selected new insulin analogues is tested in male, healthy, normoglycemic beagle dogs.
  • Male animals are injected subcutaneously with a dose of 6 nmol / kg of an insulin analogue.
  • blood samples are taken from the animals and the blood sugar content is determined therein.
  • the experiment clearly shows (see Fig. 2) that the insulin analog according to the invention used is a clear one
  • the hypoglycemic effect of selected new insulin analogues is tested in male, healthy, normoglycemic beagle dogs.
  • Male animals are injected subcutaneously with a dose of 6 nmol / kg and 12 nmol / kg of an insulin analogue.
  • blood samples are taken from the animals and the blood sugar content is determined therein.
  • Example 8 Evaluation of the hypoglycemic effect in dogs at different zinc concentrations in the formulation
  • FIG. 4 shows the result. Thereafter, the time-effect curve of the insulin analog according to the invention by the content of zinc ions in the formulation at the same concentration of insulin influence in such a way that at zero or low zinc content observed a rapid onset and the effect persists over 24 hours, while at higher zinc content low onset of action is observed and the insulin action persists well longer than 24 hours.
  • Example 9 The insulin analog according to the invention was dissolved at a target concentration of 240 + 5 ⁇ M in 1 mM hydrochloric acid with 80 ⁇ g / ml zinc (as zinc chloride).
  • a target concentration 240 + 5 ⁇ M in 1 mM hydrochloric acid with 80 ⁇ g / ml zinc (as zinc chloride).
  • the freeze-dried material was first weighed about 30% higher amount than required due to the molecular weight and the desired concentration. Thereafter, the present concentration was determined by means of analytical HPLC and the solution was then filled to the required volume to achieve the target concentration with 5 mM hydrochloric acid with 80 ug / mL zinc. If necessary, the pH was readjusted to 3.5 + 0.1.
  • the final solution was transferred via syringe with a 0.2 ⁇ m filter attachment to a sterile vial sealed with a septum and crimp cap.
  • the formulations eg with regard to an addition of isotonic agents, preservatives or buffer substances, was carried out.
  • Example 10 Evaluation of the hypoglycemic effect of novel insulin analogues in the rat
  • the hypoglycemic effect of selected new insulin analogs is tested in male, normal, normoglycemic Wistar rats.
  • Male rats are injected subcutaneously with a dose of 9 nmol / kg of an insulin analogue.
  • blood samples are taken from the animals and the blood sugar content is determined therein.
  • the experiment clearly shows (compare Fig. 4) that the insulin analog according to the invention leads to a significantly delayed onset of action and a longer, uniform duration of action.
  • Example 11 Evaluation of the hypoglycemic effect of new insulin analogues in the dog The hypoglycemic effect of selected new insulin analogues is tested in male, healthy, normoglycemic beagle dogs. Male animals are injected subcutaneously with a dose of 6 nmol / kg of an insulin analogue. Immediately before injecting the insulin analogue and at regular intervals up to forty-eight hours after the injection, blood samples are taken from the animals and the blood sugar content is determined therein. The experiment clearly shows that the insulin analog according to the invention leads to a markedly delayed, shallow onset of action and a longer, uniform duration of action.

Abstract

L'invention concerne des formulations pharmaceutiques aqueuses présentant un analogue de l'insuline qui renferme 0,001 à 0,2 mg/ml de zinc, 0,1 à 5,0 mg/ml d'un agent conservateur, et 5,0 à 100 mg/ml d'un agent isotonisant, et dont le pH est égal ou inférieur à 5. L'invention concerne en outre leur production, leur utilisation pour le traitement du diabète mellitus, et un médicament pour le traitement du diabète mellitus.
EP10726993A 2009-07-06 2010-07-02 Préparations d'insuline à effet retard Withdrawn EP2451471A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009031750 2009-07-06
DE102010013133 2010-03-27
PCT/EP2010/059438 WO2011003823A1 (fr) 2009-07-06 2010-07-02 Préparations d'insuline à effet retard

Publications (1)

Publication Number Publication Date
EP2451471A1 true EP2451471A1 (fr) 2012-05-16

Family

ID=43428815

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10726993A Withdrawn EP2451471A1 (fr) 2009-07-06 2010-07-02 Préparations d'insuline à effet retard

Country Status (7)

Country Link
US (1) US20120232002A1 (fr)
EP (1) EP2451471A1 (fr)
JP (1) JP5675799B2 (fr)
AR (1) AR077455A1 (fr)
TW (1) TW201113032A (fr)
UY (1) UY32765A (fr)
WO (1) WO2011003823A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030537T2 (en) 2008-01-09 2017-05-29 Sanofi Aventis Deutschland New insulin analogues with a particularly prolonged effect profile
SI2349324T1 (en) 2008-10-17 2018-01-31 Sanofi-Aventis Deutschland Gmbh The combination of insulin and agonist GLP-1
BR112012000177B1 (pt) * 2009-07-06 2021-06-01 Sanofi-Aventis Deutschland Gmbh Formulação farmacêutica aquosa contendo metionina, processo para sua preparação, uso da mesma e medicamento para tratar diabetes mellitus
AR078973A1 (es) 2009-11-13 2011-12-14 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
KR101836070B1 (ko) * 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
SI2611458T1 (sl) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX370264B (es) 2011-08-29 2019-12-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
AU2015205621A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2016001862A1 (fr) 2014-07-04 2016-01-07 Wockhardt Limited Formulations à libération prolongée d'insulines
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010937A1 (fr) * 1988-05-11 1989-11-16 Novo Nordisk A/S Analogues d'insuline
US6100376A (en) * 1988-11-08 2000-08-08 Hoechst Aktiengesellschaft A21, B30, modified insulin derivatives having an altered action profile
WO2007081824A2 (fr) * 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5225323A (en) * 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
CA2306877A1 (fr) * 1997-10-24 1999-05-06 Eli Lilly And Company Compositions d'insuline insolubles
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
EP1076066A1 (fr) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
WO2002067969A2 (fr) * 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Compositions d'insuline stabilisees
MXPA05003335A (es) * 2002-10-02 2005-07-05 Zealand Pharma As Compuestos de exendina-4 estabilizados.
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
KR101729986B1 (ko) * 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
HUE030537T2 (en) * 2008-01-09 2017-05-29 Sanofi Aventis Deutschland New insulin analogues with a particularly prolonged effect profile
BR112012000177B1 (pt) * 2009-07-06 2021-06-01 Sanofi-Aventis Deutschland Gmbh Formulação farmacêutica aquosa contendo metionina, processo para sua preparação, uso da mesma e medicamento para tratar diabetes mellitus
WO2011003820A1 (fr) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Préparations d'insuline stables à la chaleur et aux agitations
KR101836070B1 (ko) * 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010937A1 (fr) * 1988-05-11 1989-11-16 Novo Nordisk A/S Analogues d'insuline
US6100376A (en) * 1988-11-08 2000-08-08 Hoechst Aktiengesellschaft A21, B30, modified insulin derivatives having an altered action profile
WO2007081824A2 (fr) * 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARKUSSEN J ET AL: "SOLUBLE, PROLONGED-ACTING INSULIN DERIVATIVES. I. DEGREE OF PROTRACTION AND CRYSTALLIZABILITY OF INSULINS SUBSTITUTED IN THE TERMINI OF THE B-CHAIN", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 1, no. 3, 1 June 1987 (1987-06-01), pages 205 - 213, XP000000187, ISSN: 0269-2139 *
See also references of WO2011003823A1 *

Also Published As

Publication number Publication date
JP2012532179A (ja) 2012-12-13
TW201113032A (en) 2011-04-16
JP5675799B2 (ja) 2015-02-25
WO2011003823A1 (fr) 2011-01-13
AR077455A1 (es) 2011-08-31
UY32765A (es) 2011-01-31
US20120232002A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
EP2451437B1 (fr) Préparations aqueuses de l'insuline contenant de la méthionine
EP2451471A1 (fr) Préparations d'insuline à effet retard
EP1517697B1 (fr) Preparations acides d'insuline ayant une meilleure stabilite
EP3417871B1 (fr) Composition pharmaceutique comprenant un agoniste glp-1, de l'insuline et de la methionine
EP3345593B1 (fr) Composition pharmaceutique comprenant despro36exendin-4(1-39)-lys6-nh2 et de la méthionine
EP3228320B1 (fr) Combinaison d'une insuline et d'un antagoniste glp 1
EP2229407B1 (fr) Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé
EP1381385B1 (fr) Preparations d'insuline a stabilite amelioree, exemptes de zinc ou a faible teneur en zinc
EP2451472A1 (fr) Préparations d'insuline stables à la chaleur et aux agitations
DE102008003568A1 (de) Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008053048A1 (de) Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008003566A1 (de) Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE69919533T2 (de) Proteinhaltige arzneimittel
DE102008025008A1 (de) Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008051834A1 (de) Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de) Kombination von einem Insulin und einem GLP-1-Agonisten
DE102010011919A1 (de) Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140801

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160525